FIGURE 1.

Flowchart of study design. *Patients with known CFRD were excluded. **OGTT was performed 3 days to 6 weeks before the start with ELX/TEZ/IVA, except for three patients in whom OGTT was performed earlier (10 weeks, 4 months, and 6 months before the start) due to organizational reasons during routine clinical visits and disagreement of the patients to perform another OGTT. ***OGTT was performed 3–6 weeks after starting ELX/TEZ/IVA treatment, except for two patients in whom OGTT was performed after 8 and 10 weeks, respectively. All patients continued using ELX/TEZ/IVA until the second OGTT was performed. ⁺CGM measures were performed 3 days before and 7 days after starting with ELX/TEZ/IVA. In one patient, CGM was only installed 2 days before the initiation of ELX/TEZ/IVA therapy due to organizational reasons in routine clinical visits.